Navigation Links
Treatment Corrects Severe Insulin Imbalance in Animal Studies
Date:7/31/2008

ry on the tiny organ can remove the lesion and cure HI. The Children's Hospital of Philadelphia is a world leader in diagnosing such lesions and performing the curative surgery on newborns.

However, when abnormal cells are distributed throughout the pancreas in so-called diffuse HI, surgeons must remove nearly all the pancreas. This relieves HI in about a quarter of cases, but leaves the majority of patients at high risk for insulin imbalance, in which blood glucose levels are too low (hypoglycemia) or too high, resulting in diabetes.

The new study makes use of a peptide (an amino acid compound) called exendin-(9-39) that blocks the action of a specific hormone receptor in beta cells. Building on their previous work using exendin-(9-39) on normal mice, De Leon's study team studied the peptide's effect on a strain of mice that had been genetically engineered to mimic the defect found in children with congenital HI.

When researchers withhold food from those mice, their blood glucose levels become low, a condition called fasting hypoglycemia. Mice who had received exendin-(9-39), however, had significantly higher levels of fasting blood glucose compared to mice that were not treated with the peptide, and reached levels comparable to those in normal, healthy animals. Further studies identified the mechanisms in the hormone signaling system that malfunctions in HI.

The next step, says De Leon, is a pilot study now under way to test the effect of exendin-(9-39) in children and adults with congenital HI. If results from the pilot study are promising, her study team expects to progress to a larger clinical trial. "If this peptide can be developed into a treatment for children with this common form of HI, we may have a new tool for controlling their insulin levels and managing their disease," added De Leon.

The Congenital Hyperinsulinism Center at Children's Hospital has worldwide prominence in diagnosing and treating this genetic disease.
'/>"/>

SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
2. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
3. Four Alzheimers Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
4. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
7. Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
8. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
9. MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
10. InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
11. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free ... ), Eli Lilly and Company (NYSE: LLY - Free ... and InterMune, Inc. (Nasdaq: ITMN - Free Report ). ...
(Date:7/21/2014)... , July 21, 2014   Regulus ... biopharmaceutical company leading the discovery and development of ... U.S. Food & Drug Administration (FDA) has granted ... chemically modified oligonucleotide that binds to and inhibits ... for the treatment of Alport syndrome, a life-threatening ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Feb. 8, 2011 DURECT Corporation (Nasdaq: ... has launched commercial sales of its Food and Drug ... injectable animal health drug utilizing DURECT,s SABER™ technology to ... on net sales of SucroMate and will supply one ...
... DIEGO, Feb. 8, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the 13th Annual Bio CEO & Investor Conference on Tuesday, ...  The conference is being held at the Waldorf-Astoria Hotel in ... Officer of Anadys, will provide an overview of Anadys and ...
Cached Medicine Technology:DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference 2
(Date:7/21/2014)... for Public Affairs Research has released the results of ... it means to be a quality health care provider ... Robert Wood Johnson Foundation, sheds new light on how ... and doctors, as well as the information they use ... produces new and actionable data during a crucial period ...
(Date:7/21/2014)... Western University of Health Sciences ... For” by the Chronicle of Higher Education for ... Honor Roll for the first time. , WesternU ... and Benefits, Confidence in Senior Leadership, Job Satisfaction, ... “Western University of Health Sciences is a great ...
(Date:7/21/2014)... -- Good parenting and life skills coaching seem ... a new study suggests. Inflammation is a ... to a number of illnesses, according to Northwestern ... childhood and adulthood involve excessive inflammation. The process ... and some cancers," study author Gregory Miller, a ...
(Date:7/21/2014)... A new study suggests that potential help in ... your refrigerator. The study found that regular intake ... or supplements, may help ease the condition. Researchers ... between probiotics and blood pressure. The studies involved a ... blood pressure. People who consumed probiotics had an ...
(Date:7/21/2014)... may be getting women to go to the hospital more ... shows women have longer hospital stays and are more likely ... attack. , In the study published online today in the ... from Yale School of Medicine analyzed 230,684 hospitalizations for heart ... of 1.1 million hospitalizations reported in a national database from ...
Breaking Medicine News(10 mins):Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... to Cover Medical Devices, ARLINGTON, Va., Nov. 2 ... Capital Markets) today announced that,Christopher Warren has joined FBR ... Analyst within its healthcare group and will,focus on the ... of experience in equity research, and we,value the disciplined, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... offer convertible senior notes. The decision not to ... due principally to prevailing,market conditions resulting in note ... Note Regarding Forward-Looking Statements This release contains ...
... Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry Guidewire, ... the intellectual,property portfolio related to its chronic total ... enhanced optical sensing capabilities,allowing it to sense locations, ...
... Just how much of the time,that sales people should be ... internal communication? Pharmaceutical sales directors agree the answer is ... for internal communication - or 6 weeks per rep,per year ... year,according to a recent research study by Best Practices, LLC. ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) will announce ... 8, 2007, after market close. The announcement ... followed by a conference call and live webcast ... 4:30 p.m. Eastern. Interested parties may access the,live ...
Cached Medicine News:Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
... new Breast Overlay Apron ... provide extra coverage for ... adjustable velcro flaps allow ... fit, plust added coverage ...
Lap pad used to protect pelvic regions...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Medicine Products: